Oncolytics Biotech Inc.ONCYNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank95
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P95
Near historical high
vs 2Y Ago
2.3x
Strong expansion
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 122.33% |
| Q2 2025 | -0.57% |
| Q1 2025 | -18.55% |
| Q4 2024 | 11.47% |
| Q3 2024 | 30.16% |
| Q2 2024 | -16.59% |
| Q1 2024 | -29.97% |
| Q4 2023 | 6.69% |
| Q3 2023 | 52.87% |
| Q2 2023 | 9.32% |
| Q1 2023 | -12.85% |
| Q4 2022 | 50.32% |
| Q3 2022 | -18.66% |
| Q2 2022 | 8.70% |
| Q1 2022 | -32.24% |
| Q4 2021 | 31.70% |
| Q3 2021 | -18.97% |
| Q2 2021 | 14.07% |
| Q1 2021 | 59661.86% |
| Q4 2020 | 62.94% |
| Q3 2020 | -19.25% |
| Q2 2020 | 1.84% |
| Q1 2020 | -27.57% |
| Q4 2019 | 125.33% |
| Q3 2019 | 1.88% |
| Q2 2019 | 0.47% |
| Q1 2019 | -24.56% |
| Q4 2018 | 61.77% |
| Q3 2018 | -10.41% |
| Q2 2018 | -7.02% |
| Q1 2018 | -99.92% |
| Q4 2017 | 64.81% |
| Q3 2017 | -9.34% |
| Q2 2017 | 13.19% |
| Q1 2017 | -28.64% |
| Q4 2016 | 51.78% |
| Q3 2016 | 9.04% |
| Q2 2016 | -17.78% |
| Q1 2016 | -11.74% |
| Q4 2015 | 31.65% |